echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Tianyu Pharmaceutical's rivaroxaban API obtained CEP certificate

    Tianyu Pharmaceutical's rivaroxaban API obtained CEP certificate

    • Last Update: 2022-03-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 27, Tianyu Pharmaceutical announced that the company received the CEP certificate for rivaroxaban API issued by the European Agency for the Quality of Medicines


    Rivaroxaban is an anticoagulant drug for the prevention of venous thrombosis (VTE) in adults undergoing hip or knee replacement surgery; or for the treatment of deep vein thrombosis (DVT) in adults to reduce DVT recurrence after acute DVT and risk of pulmonary embolism (PE); or in adults with nonvalvular atrial fibrillation to reduce the risk of stroke and systemic embolism


    In October 2020, the company submitted a drug registration application for rivaroxaban API to EDQM and obtained a CEP certificate


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.